Systemic opioid and chronic pain

European Journal of Pain Supplements

Volumn 3, Issue 2, 2009, Pages 77-83

  Varrassi, Giustino ^a   Angeletti, Chiara ^a   Guetti, Cristiana ^a   Marinangeli, Franco ^a   Paladini, Antonella ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Administration routes; Chronic pain; Nociception; Opioid analgesics; Opioid receptors

Indexed keywords

ANTICONVULSIVE AGENT; BUPRENORPHINE; BUTORPHANOL; FENTANYL; HYDROMORPHONE; KETAMINE; KETAZOCINE; METHADONE; MORPHINE; MORPHINE SULFATE; N ALLYLNORMETAZOCINE; NALBUPHINE; NALORPHINE; NARCOTIC ANALGESIC AGENT; OPIATE RECEPTOR; OXYCODONE; OXYMORPHONE; PENTAZOCINE; SUFENTANIL; TRAMADOL;

ANALGESIA; ARTICLE; CANCER PAIN; CHRONIC PAIN; CONFUSION; CONSTIPATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FIRST PASS EFFECT; HUMAN; INFLAMMATION; INTRACTABLE PAIN; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROPATHIC PAIN; NEUROPHYSIOLOGY; NOCICEPTION; NONHUMAN; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RESPIRATION DEPRESSION; SKIN MANIFESTATION; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 70350571715     PISSN: 17543207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eujps.2009.08.001     Document Type: Article

References (58)

1. ® Product Information, 1998.
2. Ballantyne J.C., and Mao J. Opioid therapy for chronic pain. New Engl J Med 349 (2003) 1943-1953
3. Ballantyne J.C. Opioid analgesia: perspectives on right use and utility. Pain Phys 10 (2007) 479-491
4. Ballantyne J.C., and Shin N.S. Efficacy of opioids for chronic pain: a review of the evidence. Clin J Pain 24 (2008) 469-478
5. Barbacid M. Structural and functional properties of the TRK family of neurotrophin receptors. Ann NY Acad Sci 766 (1995) 442-458
6. Böger R.H. Renal impairment: a challenge for opioid treatment? The role of buprenorphine. Palliative Med 20 (2006) s17-s23
7. Böhme K. Buprenorphine in a transdermal therapeutic system - a new option. Clin Rheumatol 21 (2002) S13-S15
8. Borenstein D. Opioids: to use or not to use? That is the question. Arthritis Rheum 52 (2005) 6-10
9. Brewster D., Humphrey M.J., and Mcleavy M.A. Biliary excretion, metabolism and enterohepatic circulation of buprenorphine. Xenobiotica 11 (1981) 189-196
10. Bridel F. I farmaci che hanno cambiato la vita. Ed. L'Ariete, Milano; 1988.
11. Bruera E., Brenneis C., and MacDonald R.N. Continuous Sc infusion of narcotics for the treatment of cancer pain: an update. Cancer Treat Rep 71 (1987) 953-958
12. Budd K. Buprenorphine and the transdermal system: the ideal match in pain management. Int J Clin Pract 133 (2002) 9-14
13. Calis K.A., Kohler D.R., and Corso D.M. Transdermally administered fentanyl for pain management. Clin Pharmacokinet 11 (1992) 22-36
14. Christoph T., Kögel B., Schiene K., Meen M., De Vry J., and Friderichs E. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 507 (2005) 87-98
15. Clark J.D., Shi X., Li X., Qiao Y., Liang D., Angst M.S., et al. Morphine reduced local cytokine expression and neutrophil infiltration after incision. Mol Pain 3 (2007) 28
16. Collett B.J. Chronic opioid therapy for non-cancer pain. Br J Anaesth 87 (2001) 133-143
17. Corneo AC. Il dolore nei secoli tra curiosità e storia. Doc Scient Ricordati; 1986.
18. Filitz J., Griessinger N., Sittl R., Likar R., Schüttler J., and Koppert W. Effects of intermittent haemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain 10 (2006) 743-748
19. Foley K.M. Opioids and chronic neuropathic pain. New Engl J Med 348 (2003) 1279-1281
20. Glynn C., Dawson D., and Sanders R. A double-blind comparison between epidural morphine and epidural clonidine in patients with chronic non-cancer pain. Pain 34 (1988) 123-128
21. Hair P.I., Keating G.M., and McKeage K. Transdermal matrix fentanyl membrane patch (matrifen): in severe cancer-related chronic pain. Drugs 68 (2008) 2001-2009
22. Hand C.W., Sear J.W., Uppington J., and Ball M.J. Buprenorphine deposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth 64 (1990) 276-282
23. Hanning C.D. The rectal absorption of opioids. In: Benedetti C., Chapman C.R., and Giron G. (Eds). Advances in pain research and therapy vol. 14 (1990), Lippincott-Raven, Philadelphia 259-268
24. Hans G. Buprenorphine - a review of its role in neuropathic pain. J Opioid Manage 3 (2007) 195-206
25. Haythornthwaite J.A., Menefee L.A., Quatrano- Piacentini A.L., and Pappagallo M. Outcome of chronic opioid therapy for non-cancer pain. J Pain Symptom Manage 15 (1998) 185-194
26. Heel R.C., Brogden R.N., Speight T.M., and Avery G.S. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs 17 (1979) 81-110
27. Jacox A., Carr D.B., and Payne R. New clinical-practice guidelines for the management of pain in patients with cancer. N Engl J Med 330 (1994) 651-655
28. Jamison R.N., Raymond S.A., Slawsby E.A., Nedeljkovic S.S., and Katz N.P. Opioid therapy for chronic noncancer back pain: a randomized prospective study. Spine 23 (1998) 2591-2600
29. Koppert W., Ihmsen H., Körber N., Wehrfritz A., Sittl R., Schmelz M., et al. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain 118 (2005) 15-22
30. Kress H.G., Von der Laage D., Hoerauf K.H., Nolte T., Heiskanen T., Petersen R., et al. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. J Pain Symptom Manage 36 (2008) 268-279
31. Kress H.G. Buprenorphine in patients with increased vulnerability to potential opioid adverse effects. In: Budd K., and Raffa R. (Eds). Buprenorphine - the unique opioid analgesic (2005), Thieme Verlag KG, Stuttgart 79-91
32. Largent-Milnes T.M., Guo W., Wang H.Y., Burns L.H., and Vanderah T.W. Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling. J Pain 9 (2008) 700-713
33. Leca AP. La medicine egytienne au temps des Pharaones. Ed. Roger Da costa, Paris; 1971.
34. Likar R., and Sittl R. Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies. Anesth Analg 100 (2005) 781-785
35. McCarberg B.H., and Barkin R.L. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther 8 (2001) 181-186
36. McCleane G., and Smith H. Opioids for persistent noncancer pain. Med Clin N Am 91 (2007) 177-197
37. Meldrum M.L. A capsule history of pain management. JAMA 290 (2003) 2470-2475
38. Mystakidou K., Tsilika E., Tsiatas M., and Vlahos L. Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology. Int J Nanomed 2 (2007) 49-54
39. Nathan J.I. Chronic pain treatment: a high moral imperative with offsetting personal risks for the physician - a medical student's perspective. Pain Pract 9 (2009) 155-163
40. Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 63 (2003) 17-32
41. Paracelsus. Opera medico-chemica sive paradoxa. Frankfurt am Mein; 1605.
42. Portenoy R.K. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 11 (1996) 203-217
43. Rej R. Historie de la douleur. Ed. la Decouverte, Paris; 1993.
44. 35]-GTP-γ-S functional binding assay. Synapse 34 (1999) 83-94
45. Rosseland L.A., Stubhaug A., Grevbo F., Reikeras O., and Breivik H. Effective pain relief from intra-articular saline with or without morphine 2 mg in patients with moderate-to-severe pain after knee arthroscopy: a randomized, double-blind controlled clinical study. Acta Anaesth Scand 47 (2003) 732-738
46. Rowbotham M.C., Twilling L., Davies P.S., Reisner L., Taylor K., and Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. New Engl J Med 348 (2003) 1223-1232
47. Savage S.R. Long-term opioid therapy: assessment of consequences and risks. J Pain Symptom Manage 11 (1996) 274-286
48. Sertürner F.W. Uber das morphium eine neue salzfahige. Grundlage und die mekonsaure als hauptbestandtheile des opiums. Gilbert's Ann D Phys 55 (1817) 56-89
49. Simonnet G. Opioids: from analgesia to antihyperelgesia?. Pain 118 (2005) 8-9
50. Sittl R., Likar R., and Poulsen-Nautrup B. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and non-cancer pain: results of a retrospective cohort study. Clin Ther 27 (2005) 225-237
51. Sloan P., and Babul N. Extended-release opioids for the management of chronic non-malignant pain. Expert Opin Drug Deliv 3 (2006) 489-497
52. Storey P., Hill Jr. H.H., St Louis R.H., and Tarver E.E. Subcutaneous infusions for control of cancer symptoms. J Pain Symtom Manage 5 (1990) 33-40
53. Swanson G., Smith J., Bulich R., New P., and Shiffman R. Patient-controlled analgesia for chronic cancer pain in the ambulatory setting: a report of 117 patients. J Clin Oncol 7 (1989) 1903-1908
54. Sydenham T. Opera Omnia Medica I. Ed. Manfrè. Padova; 1700.
55. Trescot A.M., Glaser S.E., Hansen H., Benyamin R., Patel S., and Manchikanti L. Effectiveness of opioids in the treatment of chronic non-cancer pain. Pain Phys 11 (2008) S181-S200
56. Vallerand A.H. The use of long-acting opioids in chronic pain management. Nurs Clin North Am 38 (2003) 435-445
57. Weinberg D.S., Inturrisi C.E., Reidenberg B., Moulin D.E., Nip T.J., Wallenstein S., et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 44 (1988) 335-342
58. Wisconsin Medical Society. Task force on pain management. Guidelines for the assessment and management of chronic pain. Wisc Med J 103 (2004) 13-42